Citi analyst Yigal Nochomovitz raised the firm’s price target on Arcus Biosciences (RCUS) to $54 from $47 and keeps a Buy rating on the shares. The firm upped the probability of success for domvanalimab plus zimberelimab following the Phase 2 data.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Positive Outlook for Arcus Biosciences Driven by Promising Phase 2 Trial Results and Broader Patient Applicability
- Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study
- Arcus Biosciences price target raised to $39 from $32 at Truist
- Arcus Biosciences’ Casdatifan Shows Superior Efficacy and Safety in ccRCC Treatment, Supporting Buy Rating
- Arcus Biosciences: Promising Efficacy and Manageable Safety Profile Drive Buy Rating